The KCNG3 antibody targets the potassium voltage-gated channel subfamily G member 3 (KCNG3), a protein encoded by the *KCNG3* gene in humans. KCNG3 belongs to the voltage-gated potassium (Kv) channel family, which regulates electrical signaling in excitable cells by controlling potassium ion flow. Structurally, KCNG3 forms tetrameric channels with six transmembrane domains and a pore-forming loop, typically functioning as modulatory or regulatory subunits that alter the kinetics or voltage sensitivity of other Kv α-subunits (e.g., KCNB1).
KCNG3 is predominantly expressed in the central nervous system, including the hippocampus and cortex, and in peripheral tissues like the pancreas. Its physiological roles remain less characterized compared to other Kv channels, but it is implicated in neuronal excitability, action potential repolarization, and cellular secretion processes. Dysregulation of Kv channels is linked to neurological disorders, epilepsy, and metabolic diseases, though direct evidence for KCNG3 involvement is limited.
KCNG3 antibodies are essential tools for studying its expression, localization, and interaction partners. They are used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore its tissue distribution and potential pathological roles. Research applications include investigating channelopathies, neurodegenerative conditions, or pancreatic dysfunction. Commercial KCNG3 antibodies are typically validated for specificity in human, rodent, or other model organisms, aiding both basic research and therapeutic discovery efforts targeting Kv channel-associated diseases.